RANI (Rani Therapeutics Holdings) Insider Ownership: 3.16 % (As of Aug. 14, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

RANI Rani Therapeutics Holdings Inc RANI
31 GF Score
Price $0.80
! 3 Warning Signs
View Full Analysis

What is Rani Therapeutics Holdings Insider Ownership?

Rani Therapeutics Holdings RANI -0.81% 31 Insider Ownership is 3.16 % as of Aug. 14, 2026. GuruFocus rates RANI with a GF Score™ of 31/100. The stock has 3 warning signs investors should review.

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Rani Therapeutics Holdings's insider ownership is 3.16%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Rani Therapeutics Holdings's Institutional Ownership is 38.04%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Rani Therapeutics Holdings's Float Percentage Of Total Shares Outstanding is 97.32%.

Rani Therapeutics Holdings Insider Ownership Historical Data

* Premium members only.

The historical data trend for Rani Therapeutics Holdings's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rani Therapeutics Holdings Insider Ownership Chart

Rani Therapeutics Holdings Historical Data

The historical data trend for Rani Therapeutics Holdings can be seen below:

2025-07-31 2025-08-31 2025-09-30 2025-10-31 2025-11-30 2026-01-31 2026-02-28 2026-05-31 2026-06-30 2026-07-31
Insider Ownership 3.33 3.03 3.03 7.38 3.62 3.62 3.62 3.16 3.16 3.16
RANI
31GF Score
Rani Therapeutics Holdings Inc RANI
Insider Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Rani Therapeutics Holdings Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.

Frequently Asked Questions Learn more about Insider Ownership →
What does a Insider Ownership of 3.16 % mean?
Rani Therapeutics Holdings (RANI) has a Insider Ownership of 3.16 % as of Aug. 14, 2026. Insider ownership equals the percent of shares owned by company insiders relative to total shares. View historical data on Rani Therapeutics Holdings and its competitors.
Is Rani Therapeutics Holdings' Insider Ownership too high?
Rani Therapeutics Holdings' current Insider Ownership is 3.16 %. Overall, Rani Therapeutics Holdings has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Rani Therapeutics Holdings' Insider Ownership compare to ONCY and ALDX?
Rani Therapeutics Holdings' Insider Ownership of 3.16 % can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Insider Ownership for a Biotechnology company?
A good Insider Ownership depends on the Biotechnology industry context. However, Insider Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Insider Ownership mean?
A high Insider Ownership can signal that a stock is expensive relative to its fundamentals. Insider ownership equals the percent of shares owned by company insiders relative to total shares. View historical data on Rani Therapeutics Holdings and its competitors. Rani Therapeutics Holdings's current Insider Ownership is 3.16 %. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rani Therapeutics Holdings stock overvalued right now?
Rani Therapeutics Holdings (RANI) has a current Insider Ownership of 3.16 %. The current Insider Ownership is 3.16 %. Rani Therapeutics Holdings' overall GF Score™ is 31/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Insider Ownership calculated?
Insider Ownership is calculated from a company's financial statements. For Rani Therapeutics Holdings (RANI), the current Insider Ownership is 3.16 % as of Aug. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Rani Therapeutics Holdings Business Description

Address 2051 Ringwood Avenue, San Jose, CA, USA, 95131
Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads in liquid form with high bioavailability.
31GF Score

Get the complete analysis for RANI

Insider Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.80
Price